GLP-1 drugs face access gap as misuse grows, warns expert

Dr. Anoop Misra, a prominent endocrinologist and metabolic disease expert, has flagged a significant disparity in the utilization of GLP-1 receptor agonist medications across India. The concern centers on an inverse relationship between medical need and actual usage of these drugs, which are primarily indicated for managing type 2 diabetes and obesity.

According to Dr. Misra's observations, patients who would benefit most from GLP-1 therapy—those with diabetes and metabolic disorders—often lack access to these medications due to cost, availability, or awareness constraints. Conversely, individuals without clear clinical indications are obtaining and using these drugs, driven by emerging trends around weight management and cosmetic outcomes.

The growing popularity of GLP-1 drugs, particularly their use among individuals seeking weight loss without underlying diabetes or metabolic conditions, has created supply-side pressures that further limit availability for those with genuine medical need. This trend reflects broader challenges in India's healthcare system around equitable drug access and rational pharmaceutical usage.

Dr. Misra's warning underscores the need for better regulation, patient education, and healthcare infrastructure to ensure GLP-1 medications reach those for whom they offer the most clinical benefit while curbing non-medical usage patterns.